Chronic Obstructive Pulmonary Disease (COPD) Treatment Market By Drug Class (Bronchodilators, Combination Inhalers, Phosphodiesterase-4 Inhibitors, Mucolytics, Antibiotics and Oral Corticosteroids), By Route of Administration (Inhalation, Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Nov 2024 | Report ID: MI1239 | 215 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Drug Class

  • Bronchodilators
  • Combination Inhalers
  • Phosphodiesterase-4 Inhibitors
  • Mucolytics
  • Antibiotics
  • Oral Corticosteroids

By Route of Administration

  • Inhalation
  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

List of Companies:

  • GlaxoSmithKline plc
  • Boehringer Ingelheim
  • AstraZeneca
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Mylan N.V.
  • Roche Holding AG
  • Chiesi Farmaceutici S.p.A.
  • Sun Pharmaceutical Industries Ltd.
  • Lundbeck A/S
  • Meda AB
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing